scispace - formally typeset
Search or ask a question

Showing papers by "Vincent C. O. Njar published in 2000"


Journal ArticleDOI
01 Apr 2000-Steroids
TL;DR: It is evident that aromatase inhibitors can extend the duration of treatment in breast cancer patients, and these compounds recently were approved in the United States and have been shown to be more effective than other second-line agents in terms of overall response rates and treatment failure, as well as better tolerated.

107 citations


Journal ArticleDOI
TL;DR: The findings suggest that some prostate cancer patients who appear to become hormone-independent may have tumors which are stimulated by P(5) via a mutated AR and that these patients could benefit from treatment with antiestrogens, antiprogestins, or with some of the novel androgen synthesis inhibitors.

76 citations


Patent
29 Dec 2000
TL;DR: Androgen synthesis inhibitors, as well as methods for the use of the same to reduce plasma levels of testosterone and/or dyhydrotestosterone, and to treat prostate cancer and benign prostatic hypertrophy, are disclosed in this article.
Abstract: Androgen synthesis inhibitors, as well as methods for the use of the same to reduce plasma levels of testosterone and/or dyhydrotestosterone, and to treat prostate cancer and benign prostatic hypertrophy, are disclosed.

33 citations



Journal ArticleDOI
TL;DR: Novel (±)-4-azolyl retinoic acid analogues 4, 5, 7 and 8 have been designed and synthesized and have been shown to be powerful inhibitors of hamster microsomal all-trans-retINOic acid 4-hydroxylase enzyme(s).

26 citations


Journal ArticleDOI
TL;DR: Novel (±)-4-azolyl retinoic acid analogues 4, 5, 7 and 8 have been designed and synthesized and have been shown to be powerful inhibitors of hamster microsomal all-trans-retINOic acid 4-hydroxylase enzyme(s) as mentioned in this paper.
Abstract: Novel (±)-4-azolyl retinoic acid analogues 4, 5, 7 and 8 have been designed and synthesized and have been shown to be powerful inhibitors of hamster microsomal all-trans-retinoic acid 4-hydroxylase enzyme(s). (±)-4-(1H-Imidazol-1-yl)retinoic acid (4) is the most potent inhibitor of this enzyme reported to date.

2 citations